CD163 and classic Hodgkin lymphoma: CD163 was proposed as the marker of the M2-like phenotype and CD163+ TAMs and it indeed resulted in being a strong predictor of adverse outcomes in numerous series of ABVD treated cHL [48]; however, several authors challenge that CD163 can be considered a reliable M2 marker when used on its own.